The twelve questions, answered

Is sermorelin legit?

Yes, in the narrow sense that matters: sermorelin is a real, well-characterized 29-amino-acid peptide (GHRH 1-29) with two prior FDA approvals — a 1990 diagnostic NDA and a 1997 pediatric therapeutic NDA — and a documented place in Section 503A compounding today ^[1][5][12]. It is not currently an FDA-approved drug product on the US market; the manufacturer discontinued it in 2008 for commercial reasons, a determination the FDA formally accepted in 2013 ^[6]. The legal predicate for current compounding is that 2013 Federal Register finding that the withdrawal was not for safety or effectiveness reasons ^[6].

The "legit" question is usually really two questions: is the molecule real, and is the regulatory framing real? Both answers are yes — with the precise caveat that current US availability runs through state-licensed Section 503A compounding pharmacies, not through an FDA-approved drug product.

Was sermorelin ever FDA-approved?

Twice. NDA 19-863 was approved in 1990 for diagnostic use — a pituitary GH stimulation agent administered as a 1 microg/kg IV bolus ^[5]. NDA 020443 was approved in 1997 for the long-term treatment of idiopathic growth hormone deficiency in pediatric patients with growth failure, at 30 microg/kg subcutaneously at bedtime ^[5]. Both NDAs were held by the manufacturer that left the market in 2008. The 2013 Federal Register notice records both approval numbers and the determination that neither was withdrawn for reasons of safety or effectiveness ^[6].

Why was the therapeutic formulation withdrawn in 2008?

Commercial reasons, as recorded in the 2013 FDA Federal Register notice ^[6]. The agency's determination was substantive, not procedural: in order to allow generic or compounded availability of a previously approved product, the FDA must affirm that the withdrawal was not for safety or effectiveness concerns. That affirmation is exactly what the 2013 notice provided ^[6]. The 2024 FDA briefing for the Pharmacy Compounding Advisory Committee restated the same conclusion — the discontinuation was a business decision ^[17].

Is compounded sermorelin legal in the United States?

Compounded sermorelin from a state-licensed Section 503A pharmacy on a valid individual prescription is permitted under current FDA policy, with the agency treating sermorelin as a component of a formerly FDA-approved drug whose withdrawal was non-safety-related ^[12]. It sits in Category 1 of the interim 503A bulks list pending final FDA rulemaking ^[12][18]. This is a regulatory category — not an endorsement of any particular use — and the status can change with PCAC recommendations and final rulemaking; a 2025 regulatory analysis flagged that the agency continues to review compounded peptides through 2025-2026 PCAC cycles ^[18][19]. Sermorelin is not the same legal animal as a vendor-marketed grey-market peptide; the difference is the prescription, the pharmacy license, and the regulatory category.

How is sermorelin different from recombinant growth hormone?

Recombinant growth hormone supplies GH directly to the body and bypasses the pituitary. Sermorelin acts upstream — it binds the GHRH receptor on the pituitary and asks the pituitary to release its own GH in a pulse ^[1][9]. The practical consequence is that pituitary feedback control remains intact with sermorelin: somatostatin and IGF-1 still close the loop, the pulsatile sleep-entrained pattern of GH release is preserved, and intermittent dosing does not cause the tachyphylaxis seen with continuous GHRH infusion ^[9]. Recombinant GH is more potent at producing supraphysiologic GH exposures; the registration-era pediatric data show sermorelin produced sustained but less potent growth-velocity gains compared with recombinant somatropin at equivalent doses ^[1].

What is sermorelin's mechanism of action?

Sermorelin binds the GHRH receptor (GHRHR), a Gs-coupled GPCR on pituitary somatotrophs. Receptor binding activates adenylate cyclase, raises cAMP, drives PKA signalling, and increases GH gene transcription and pulsatile release ^[1]. The released GH then stimulates hepatic IGF-1 synthesis via JAK2/STAT5, and the resulting IGF-1 and somatostatin signals close the feedback loop ^[1][8]. In the original NDA-era clinical record, no off-target hormonal perturbations were reported — prolactin, LH, FSH, insulin, cortisol, glucose, glucagon, and thyroid hormones did not measurably shift ^[7]. It is a narrow signal on a single receptor in a single tissue.

What were the historical research doses of sermorelin?

Three values cover most of the literature. Diagnostic stimulation: 1 microg/kg IV bolus, the historical diagnostic-NDA protocol ^[2]. Pediatric idiopathic GHD: 30 microg/kg/day subcutaneously at bedtime, the historical pediatric-label dose used in the 1997 NDA program and replicated in the Ishida 2020 review ^[1][5][16]. Adult research-context dosing: either 1 mg subcutaneously nightly (Vittone, Baker) or 10 microg/kg subcutaneously nightly (Khorram), both 30 to 45 minutes before sleep ^[3][4][16]. The modern compounded research range reported in the literature for adult models typically falls between 100 and 500 microg subcutaneously nightly ^[16].

What is the half-life of sermorelin?

Approximately 11 to 12 minutes in plasma after either IV or subcutaneous administration ^[8]. Peak plasma concentration after SC arrives in 5 to 20 minutes, with a mean absolute SC bioavailability near 6% and plasma clearance of 2.4 to 2.8 L/min ^[8]. Clearance is largely via dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase ^[8]. The downstream effects last longer than the parent peptide: a single nightly pulse drives a 1- to 2-hour GH peak, and the resulting IGF-1 elevation persists for days after dosing stops ^[8].

How does sermorelin appear on the FDA 503A bulks list?

Sermorelin appears in Category 1 of the interim 503A bulks list, which the FDA describes as bulk drug substances nominated for use in 503A compounding that the agency has determined do not raise significant safety concerns pending final rulemaking ^[12]. The 2024 FDA PCAC briefing reaffirmed sermorelin's status as a component of a formerly FDA-approved drug product whose withdrawal was non-safety-related ^[17]. A 2025 regulatory analysis from Frier Levitt frames sermorelin as a long-standing example of a peptide permissible under 503A compounding because of that historical NDA record, and notes that the agency continues to review other peptides through 2025-2026 PCAC cycles ^[18][19]. Status is current as of publication; the bulks list remains an interim regulatory instrument.

What does the research say about sermorelin in older adults?

Two trials from 1997 anchor the literature. Vittone and colleagues gave 1 mg SC nightly to healthy elderly men (aged 64 to 76) and reported increased nocturnal GH pulse amplitude, increased 24-hour integrated GH, and IGF-1 rising into the young-adult range ^[3]. Khorram, Laughlin and Yen ran 16 weeks of nightly SC dosing in adults aged 55 to 71 with sustained nocturnal GH release and IGF-1 elevation, with no tachyphylaxis ^[4]. A companion paper reported shifts in peripheral immune populations including natural killer cell activity paralleling the IGF-1 rise ^[15]. The 2012 Baker trial reported improvements in executive function and short-term verbal memory composite scores in older adults treated with 1 mg of GHRH SC nightly for 20 weeks, with effects persisting at least 10 weeks after washout ^[16]. The body of work is small but consistent on the GH/IGF-1 axis.

Is sermorelin banned in sports?

Yes. The World Anti-Doping Agency lists GHRH analogs, including sermorelin, under Code S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). The class is prohibited both in-competition and out-of-competition. This is a sport-governance status, separate from the FDA regulatory record; athletes subject to WADA testing should treat the prohibition as binding regardless of compounding category.

Has sermorelin been studied for anything other than growth and aging?

A 2021 in silico screening study by Chang and colleagues ranked sermorelin highest among 4,865 compounds in a transcriptomic analysis of 1,018 glioma samples for recurrent glioma, with pathway analysis suggesting cell-cycle inhibition and modulation of immune-checkpoint and M0 macrophage signatures ^[10]. This is a purely computational result; the authors framed it as motivation for pre-clinical testing rather than a clinical claim, and no in vivo administration was performed in that work ^[10]. Separately, the 2012 Baker trial reported cognitive endpoints in older adults ^[16]. Outside those two lines, the substantive human literature is the pediatric GHD and elderly-adult GH/IGF-1 work.

What is the difference between sermorelin and other GHRH analogs?

Sermorelin is GHRH(1-29) without further structural modification beyond the C-terminal amide that keeps it bioactive ^[1]. Related GHRH analogs in the literature carry small substitutions or pegylation that change pharmacokinetics. The Khorram studies used [Nle27]GHRH(1-29)-NH2, a sermorelin-class analog with a single substitution at position 27 — the GH/IGF-1 response was the same family of result as native sermorelin ^[4][15]. Longer-acting GHRH analogs (CJC-1295 with DAC, for example) extend half-life from minutes to days through albumin binding, which changes the dosing rhythm but also moves the pharmacology away from the pulsatile pattern sermorelin preserves ^[8]. The shorter the half-life, the closer the dosing pattern stays to the body's own pulsatile GH rhythm — which is the design rationale for sermorelin's nightly subcutaneous protocol ^[8][9].

What does the FDA say about sermorelin today?

The current regulatory posture is summarised across three FDA documents. The 2013 Federal Register notice formally determined that the historical sermorelin acetate formulations (NDA 19-863 and NDA 020443) were not withdrawn for reasons of safety or effectiveness ^[6]. The 2023 FDA guidance on bulk drug substances used in compounding under Section 503A lists sermorelin in Category 1 of the interim 503A bulks list ^[12]. The 2024 PCAC briefing reaffirmed sermorelin's status as a component of a formerly FDA-approved drug product and treated its 503A compoundable status as a long-standing baseline while the agency continued review of other peptides ^[17]. None of these documents reauthorise sermorelin as an FDA-approved drug product; they preserve a regulatory category that permits compounding by state-licensed 503A pharmacies on individual prescriptions pending final rulemaking ^[12][18].